A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

GeneScience Pharmaceuticals (GenSci)

Status and phase

Unknown

Phase 3

Conditions

Dwarfism

Treatments

Drug: Recombinant Human Growth Hormone Injection (rhGH)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03535415

GenSci GH AQ CT-CKD

Details and patient eligibility

About

This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.

Enrollment

68 estimated patients

Sex

All

Ages

2 to 14 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed consent of the subjects or the legal guardian.
Subjects and guardian are willing and able to cooperate to complete scheduled visits,treatment plans and laboratory tests and other procedures.
Diagnosed as chronic kidney disease.
Glomerular filtration rate (GFR) <75ml/per min/1.73m2.
After the treatment and adjustment of hypertension, anemia, metabolic acidosis, malnutrition, renal osteopathy, hypothyroidism, etc..
Chronological age: ≥2years and ≤14years.
Height Standard Deviation Score(HtSDS) ≤-2SD for chronological age.
Bone age: girls≤10 years; boys≤11years.
Pre-pubertal (Tanner Stage I ) patients.
No history of growth hormone treatment.

Exclusion criteria

Subjects with abnormal liver functions.
Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests.
After adjustment heart function,Cardiac ejection fraction(EF) <50%.
Subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient.
Subjects with systemic chronic disease or general infection or mental disease.
Subjects with diabetes or impaired fasting glucose.
Subjects with tumor or potential tumor.
Subjects who are using glucocorticoid or immunosuppressant.
Other causes for growth retardation.
Inability to obtain accurate height measurements.
Subjects who took part in other clinical trials within 3 months.
Concomitant administration of other treatment that may have an effect on growth within 3 months.
Other conditions which are unsuitable for this study in the opinion of the investigator.